Enhancing exercise tolerance and physical activity in COPD with combined pharmacological and non-pharmacological interventions: PHYSACTO randomised, placebo-controlled study design

BMJ Open

Volumn 6, Issue 4, 2016, Pages

  Troosters, Thierry ^a   Bourbeau, Jean ^b   Maltais, François ^c   Leidy, Nancy ^d   Erzen, Damijan ^e   De Sousa, Dorothy ^f   Korducki, Lawrence ^g   Hamilton, Alan ^f  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b Respiratory Epidemiology and Clinical Research Unit   (Canada)

^c LAVAL UNIVERSITY   (Canada)

^d EVIDERA   (United States)

^e BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^f BOEHRINGER INGELHEIM CANADA LTD   (Canada)

^g BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OLODATEROL PLUS TIOTROPIUM BROMIDE; PLACEBO; TIOTROPIUM BROMIDE; BRONCHODILATING AGENT;

ACCELEROMETER; ADULT; ARTICLE; BEHAVIOR CHANGE; BLOOD PRESSURE; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENDURANCE; EXERCISE TOLERANCE; FORCED EXPIRATORY VOLUME; FUNCTIONAL ASSESSMENT INVENTORY; FUNCTIONAL PERFORMANCE INVENTORY SHORT FORM; HUMAN; KINESIOTHERAPY; LUNG FUNCTION; MULTICENTER STUDY; OUTCOME ASSESSMENT; OXYGEN SATURATION; PATIENT PREFERENCE; PHYSICAL ACTIVITY; RANDOMIZED CONTROLLED TRIAL; RESISTANCE TRAINING; RISK ASSESSMENT; SELF CARE; SELF REPORT; SOFT MIST INHALER; SPIROMETRY; AGED; AUSTRALIA; CANADA; CLINICAL TRIAL; DRUG EFFECTS; EUROPE; EXERCISE TEST; FEMALE; MALE; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; NEW ZEALAND; PHASE 3 CLINICAL TRIAL; PROCEDURES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; REGRESSION ANALYSIS; TREATMENT OUTCOME; UNITED STATES; WALKING;

ADULT; AGED; AUSTRALIA; BRONCHODILATOR AGENTS; CANADA; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; EUROPE; EXERCISE TEST; EXERCISE THERAPY; EXERCISE TOLERANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEW ZEALAND; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; REGRESSION ANALYSIS; RESEARCH DESIGN; SELF CARE; TREATMENT OUTCOME; UNITED STATES; WALKING;

EID: 84969964611     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2015-010106     Document Type: Article

References (53)

1. van Remoortel H, Hornikx M, Demeyer H, et al. Daily physical activity in subjects with newly diagnosed COPD. Thorax 2013;68:962-3.
2. Troosters T, van der Molen T, Polkey M, et al. Improving physical activity in COPD: Towards a new paradigm. Respir Res 2013;14:115.
3. Watz H, Pitta F, Rochester CL, et al. An official European Respiratory Society statement on physical activity in COPD. Eur Respir J 2014;44:1521-37.
4. Leidy NK, Kimel M, Ajagbe L, et al. Designing trials of behavioral interventions to increase physical activity in patients with COPD: insights from the chronic disease literature. Respir Med 2014;108:472-81.
5. ZuWallack R, Esteban C. Understanding the impact of physical activity in COPD outcomes: moving forward. Eur Respir J 2014;44:1107-9.
6. Garcia-Aymerich J, Lange P, Benet M, et al. Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: A population based cohort study. Thorax 2006;61:772-8.
7. Gimeno-Santos E, Frei A, Steurer-Stey C, et al. Determinants and outcomes of physical activity in patients with COPD: A systematic review. Thorax 2014;69:731-9.
8. Garcia-Aymerich J, Lange P, Benet M, et al. Regular physical activity modifies smoking-related lung function decline and reduces risk of chronic obstructive pulmonary disease. A population-based cohort study. Am J Respir Crit Care Med 2007;175:458-63.
9. Waschki B, Kirsten AM, Holz O, et al. Disease progression and changes in physical activity in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2015;192:295-306.
10. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2014. 2014. http://www.goldcopd.org/uploads/users/files/GOLD-Report2014-Feb07.pdf(accessed 22 Jul 2015).
11. Beeh KM, Singh D, Di Scala L, et al. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: The GLOW3 trial. Int J Chron Obstruct Pulmon Dis 2012;7:503-13.
12. Maltais F, Celli B, Casaburi R, et al. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respir Med 2011;105:580-7.
13. O'Donnell DE, Casaburi R, Vincken W, et al. Effect of indacaterol on exercise endurance and lung hyperinflation in COPD. Respir Med 2011;105:1030-6.
14. Maltais F, Hamilton A, Marciniuk D, et al. Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest 2005;128:1168-78.
15. O'Donnell DE, Voduc N, Fitzpatrick M, et al. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J 2004;24:86-94.
16. McCarthy B, Casey D, Devane D, et al. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2015;(2):CD003793.
17. Klijn P, van Keimpema A, Legemaat M, et al. Nonlinear exercise training in advanced chronic obstructive pulmonary disease is superior to traditional exercise training. A randomized trial. Am J Respir Crit Care Med 2013;188:193-200.
18. McNamara RJ, McKeough ZJ, McKenzie DK, et al. Water-based exercise in COPD with physical comorbidities: A randomised controlled trial. Eur Respir J 2013;41:1284-91.
19. Ringbaek T, Brøndum E, Martinez G, et al. Rehabilitation in COPD: The long-term effect of a supervised 7-week program succeeded by a self-monitored walking program. Chron Respir Dis 2008;5: 75-80.
20. Dias FD, Sampaio LM, da Silva GA, et al. Home-based pulmonary rehabilitation in patients with chronic obstructive pulmonary disease: A randomized clinical trial. Int J Chron Obstruct Pulmon Dis 2013;8:537-44.
21. Maltais F, Decramer M, Casaburi R, et al. An official American Thoracic Society/European Respiratory Society statement: update on limb muscle dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2014;189:e15-e62.
22. Pepin V, Saey D, Laviolette L, et al. Exercise capacity in chronic obstructive pulmonary disease: mechanisms of limitation. COPD 2007;4:195-204.
23. Burtin C, Saey D, Saglam M, et al. Effectiveness of exercise training in patients with COPD: The role of muscle fatigue. Eur Respir J 2012;40:338-44.
24. Casaburi R, Kukafka D, Cooper CB, et al. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 2005;127:809-17.
25. Nici L, Donner C, Wouters E, et al. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med 2006;173:1390-413.
26. Troosters T. Physical inactivity in patients with COPD: The next step is action. Prim Care Respir J 2013;22:391-2.
27. Beeh KM, Watz H, Puente-Maestu L, et al. Aclidinium improves exercise endurance, dyspnea, lung hyperinflation, and physical activity in patients with COPD: A randomized, placebo-controlled, crossover trial. BMC Pulm Med 2014;14:209.
28. Watz H, Krippner F, Kirsten A, et al. Indacaterol improves lung hyperinflation and physical activity in patients with moderate chronic obstructive pulmonary disease-a randomized, multicenter, double-blind, placebo-controlled study. BMC Pulm Med 2014;14:158.
29. Troosters T, Sciurba FC, Decramer M, et al. Tiotropium in patients with moderate COPD naive to maintenance therapy: A randomised placebo-controlled trial. NPJ Prim Care Respir Med 2014;24:14003.
30. Effing T, Zielhuis G, Kerstjens H, et al. Community based physiotherapeutic exercise in COPD self-management: A randomised controlled trial. Respir Med 2011;105:418-26.
31. Hospes G, Bossenbroek L, ten Hacken NH, et al. Enhancement of daily physical activity increases physical fitness of outclinic COPD patients: results of an exercise counseling program. Patient Educ Couns 2009;75:274-8.
32. de Blok BMJ, de Greef MHG, ten Hacken NHT, et al. The effects of a lifestyle physical activity counseling program with feedback of a pedometer during pulmonary rehabilitation in patients with COPD: A pilot study. Patient Educ Couns 2006;61:48-55.
33. Mendoza L, Horta P, Espinoza J, et al. Pedometers to enhance physical activity in COPD: A randomised controlled trial. Eur Respir J 2015;45:347-54.
34. Altenburg WA, ten Hacken NHT, Bossenbroek L, et al. Short- And long-term effects of a physical activity counselling programme in COPD: A randomized controlled trial. Respir Med 2015;109:112-21.
35. Bourbeau J, Lavoie LK, Sedeno M, et al. Behaviour-change intervention in a multicentre, randomised, placebocontrolled COPD study: methodological considerations and implementation. BMJ Open 2016;6:e010109.
36. Leidy NK, Hamilton A, Becker K. Assessing patient report of function: content validity of the Functional Performance Inventory-Short Form (FPI-SF) in patients with chronic obstructive pulmonary disease (COPD). Int J Chron Obstruct Pulmon Dis 2012;7:543-54.
37. Leidy NK, Knebel A. In search of parsimony: reliability and validity of the Functional Performance Inventory-Short Form. Int J Chron Obstruct Pulmon Dis 2010;5:415-23.
38. Dobbels F, de Jong C, Drost E, et al. The PROactive innovative conceptual framework on physical activity. Eur Respir J 2014;44:1223-33.
39. Gimeno-Santos E, Raste Y, Demeyer H, et al. The PROactive instruments to measure physical activity in patients with chronic obstructive pulmonary disease. Eur Respir J 2015;46: 988-1000.
40. Blair HA, Deeks ED. Umeclidinium/vilanterol: A review of its use as maintenance therapy in adults with chronic obstructive pulmonary disease. Drugs 2015;75:61-74.
41. Prakash A, Babu KS, Morjaria JB. Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD. Int J Chron Obstruct Pulmon Dis 2015;10:111-23.
42. US Food and Drug Administration. NDA 203-975: umeclidinium and vilanterol inhalation powder for the long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). 2013. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM367411.pdf (accessed 22 Jan 2016).
43. Living Well with COPD™. 2015. http://www.livingwellwithcopd.com/en/home.html(accessed 12 Jan 2015).
44. Spruit MA, Singh SJ, Garvey C, et al. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med 2013;188:e13-e64.
45. Holland AE, Spruit MA, Troosters T, et al. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur Respir J 2014;44:1428-46.
46. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005;26:319-38.
47. Nici L, ZuWallack R, American Thoracic Society Subcommittee on Integrated Care of the COPD Patient. An official American Thoracic Society workshop report: The Integrated Care of The COPD Patient. Proc Am Thorac Soc 2012;9:9-18.
48. Leidy NK. Using functional status to assess treatment outcomes. Chest 1994;106:1645-6.
49. Stull DE, Leidy NK, Jones PW, et al. Measuring functional performance in patients with COPD: A discussion of patient-reported outcome measures. Curr Med Res Opin 2007;23:2655-65.
50. Bauman AE, Reis RS, Sallis JF, et al. Correlates of physical activity: why are some people physically active and others not? Lancet 2012;380:258-71.
51. Thorpe O, Kumar S, Johnston K. Barriers to and enablers of physical activity in patients with COPD following a hospital admission: A qualitative study. Int J Chron Obstruct Pulmon Dis 2014;9:115-28.
52. Demeyer H, Burtin C, van Remoortel H, et al. Standardizing the analysis of physical activity in patients with COPD following a pulmonary rehabilitation program. Chest 2014;146: 318-27.
53. Chan AW, Tetzlaff JM, Gotzsche PC, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ 2013;346:e7586.